VANCOUVER, BC--(Marketwire - June 09, 2008) - TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that the company has executed an exclusive option agreement with The University of British Columbia (UBC) for three follow on technologies related to the original TAP-technology acquired by the company from UBC on May 31, 2007.
